Home | Welcome to Contract Pharma   
Last Updated Saturday, April 19 2014

Orion Signs License Agreement with Janssen

By Kristin Brooks

Published December 20, 2013
Related Searches: Development
Orion Corp. has entered into a license agreement with Janssen Pharmaceuticals for the development and commercialization of Orion's investigational alpha-2c adrenoceptor antagonists for the symptoms of Alzheimer's disease, including clinical phase compound ORM-12741.
Orion will receive an upfront payment of $31 million and is eligible to receive payments upon completion of certain development and commercialization milestones, as well as royalties on future sales. Orion will use the majority of the up-front payment for costs associated with an additional Phase IIa study.
Orion will have exclusive commercialization rights in Europe and will grant Janssen a worldwide license to develop ORM-12741 and other compounds from the alpha-2c platform. Janssen will have an exclusive right to commercialize these compounds outside Europe. Orion and Janssen will co-fund development the Phase IIa study is completed.
Dr. Reijo Salonen, senior vice president of R&D at Orion, said, "In our collaboration with Janssen, I believe we will have the best of all worlds. At Janssen, there is a track record of success and commitment of developing therapies in Neurosciences. At Orion, we have a track record of inventing innovative molecules; and for Alzheimer patients, we hope that this partnership will bring them a novel medicine that will make an important difference to their lives."

blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On